Skip to main content

Advertisement

SpringerLink
Log in

Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Cros E, Jordheim L, Dumontet C, Galmarini CM . Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma 2004; 45: 1123–1132.

    Article  CAS  Google Scholar 

  2. Emanuel PD . Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004; 3: 203–209.

    PubMed  Google Scholar 

  3. Largaespada DA, Shaughnessy Jr JD, Jenkins NA, Copeland NG . Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol 1995; 69: 5095–5102.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG . Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996; 12: 137–143.

    Article  CAS  Google Scholar 

  5. Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003; 97: 441–449.

    Article  CAS  Google Scholar 

  6. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332–337.

    Article  CAS  Google Scholar 

  7. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K . The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005; 102: 8573–8578.

    Article  CAS  Google Scholar 

  8. Milella M, Kornblau SM, Andreeff M . The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 2003; 7: 160–190.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported by the Leukemia and Lymphoma Society of America (LLS 7019–04, Specialized Center of Research).

Author information

Authors and Affiliations

  1. Department of Genetics, Cell Biology and Development, The Cancer Center at the University of Minnesota, University of Minnesota, Minneapolis, MN, USA

    B Yin, K Morgan, D E Hasz, Z Mao & D A Largaespada

Authors
  1. B Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D E Hasz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D A Largaespada
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yin, B., Morgan, K., Hasz, D. et al. Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia 20, 151–154 (2006). https://doi.org/10.1038/sj.leu.2404033

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404033

  • Springer Nature Limited

This article is cited by

Search

Navigation